OncoMatch/Clinical Trials/NCT07646145
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
Official title: Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Medium-high Risk Non-Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial
Is NCT07646145 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including Disitamab Vedotin and Mitomycin C (MMC) for non-muscle-invasive bladder cancer (nmibc).
Treatment: Disitamab Vedotin · Mitomycin C (MMC) — This study aims to evaluate the efficacy and safety of intravenous administration of vedacitinib combined with intravesical instillation of mitomycin in treating patients with high-risk NMIBC with HER2 expression. The goal is to provide a new treatment option for NMIBC patients, reduce the risk of tumor recurrence, decrease the proportion of radical bladder surgery, and improve the quality of life of patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Urothelial Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) expression (ihc 1+, 2+ or 3+)
Prior therapy
Cannot have received: bladder radiotherapy for urothelial carcinoma
Received bladder radiotherapy for urothelial carcinoma before treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07646145 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bladder radiotherapy for urothelial carcinoma disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages